IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

exenatide Injection

exenatide Injection
Initial U.S. Approval: 2005

BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Facts about exenatide Injection 

Approval Date:  2005
Proprietary Name:  BYETTA (exenatide) Injection
Active Ingredient(s):  exenatide
FDA-approved use: 2 diabetes mellitus.
Dosage Form:  BYETTA is supplied as 250 mcg/mL exenatide in:  • 5 mcg per dose, 60 doses, 1.2 mL prefilled pen • 10 mcg per dose, 60 doses, 2.4 mL prefilled pen.
Medicine Approved By: Food and Drug Administration (FDA)
Manufacturer: Amylin Pharmaceuticals, Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Full Support:

IPN, Delhi can help with your prescription of the Registered Medical Practitioner (RMP) to get access. Based on your input information received, a step by step guide on how we can help you legally and safely import a medicine “exenatide Injection” will be provided.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For exenatide Injection

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type Exenatide, is a medication used to treat diabetes mellitus type 2. Note: (see Drugs@FDA for complete indication)

What is BYETTA? • BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. • BYETTA is not insulin. • You should not take BYETTA instead of insulin. • The use of BYETTA with insulin is not recommended. • BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. • It is not known if BYETTA is safe and effective in children. • BYETTA has not been studied in people who have pancreatitis. • BYETTA should not be used in people who have severe kidney problems.  Active Ingredient: exenatide Inactive Ingredients: metacresol, mannitol, glacial acetic acid, and sodium acetate trihydrate in water for injection.

How To access exenatide Injection?

BYETTA (exenatide) Injection Initial U.S. Approval: 2005
To access exenatide Injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398